Back to News

Kidney International® Publishes ISN First Consensus Guidance for Pre-clinical Animal Studies in Translational Nephrology 

Kidney International® has published the “International Society of Nephrology First Consensus Guidance for Pre-clinical Animal Studies in Translational Nephrology.

This open-access paper was developed from the “First Consensus Meeting on Guidance for Optimal Pre-Clinical Animal Studies in Translational Nephrology” (TRANSFORM) hosted by the ISN in Brussels, Belgium, in October 2022.

This is the first such guidance. The recommendations seek to accelerate the development of new drugs to effectively treat kidney diseases and improve the prognosis and quality of life of people living with them.

The consensus meeting connected experts in the global kidney care community to guide the optimal management of translational animal studies for developing new drugs to treat kidney disease: “TRANSFORM; TRAnslational Nephrology Science FOR new Medications.“*

Pre-clinical tests in animal models are key steps in early drug development. Drugs that work well in animals often fail to work in human trials, so it is critical to address the issue of translatability. Research guidelines to report animal studies exist; however, further expert guidance could provide additional value, particularly in planning animal studies.

Find visual summaries of all recommendations for pre-clinical animal studies in translational nephrology here.

Watch a recording of the ISN Webinar on this first consensus guidance here.

This initiative is part of ISN’s desire to grow the research capacity of the global nephrology community by identifying and coordinating strategic directions and activities aligned with ISN’s mission, vision, and values. Consider further supporting our work by becoming an ISN member.

*The ISN Research Working Group planned and launched the meeting, made possible with unrestricted educational grants from (in alphabetical order): Astra Zeneca, Aurinia Pharma, Daiichi Sankyo, Kyowa Kirin, Otsuka Pharmaceutical Co. Ltd., and Travere Therapeutics.
Help us advance kidney health worldwide
Join the ISN Subscribe to ISN Newsletter
Back to News